Mylan in patent settlement with Shionogi, CIMA for Prednisolone ODTPharmaceutical Business ReviewMylan has signed a settlement and license agreements with Shionogi and CIMA Labs regarding Prednisolone sodium phosphate orally disintegrating tablets (ODT…
Mylan settles generic Orapred ODT patent litigation with Shionogi and CIMA Labspharmabiz.comMylan Inc. has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone sodium phos…
Usada's Lance Armstrong rap sheetThe Guardian1 Use and/or attempted use of prohibited substances and/or methods including EPO, blood transfusions, testosterone, corticosteroids and/or masking agents. 2 Possession of prohibited substances and/or met…
Veloxis Pharmaceuticals to Present Data Differentiating LCP-Tacro™ from …Sacramento BeeHORSHOLM, Denmark, Oct. 10, 2012 — /PRNewswire/ — Veloxis will give two upcoming data presentations that further define the profile of LCP-Tacro compared to ot…
Mylan Announces Settlement Agreement for its First-to-File Generic Version of …Sacramento BeePITTSBURGH, Oct. 9, 2012 — /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement agreement with Shionogi Inc. and C…
Inhaled corticosteroids increase Staphylococcus pneumoniae infection riskNews-Medical.netRegular use of inhaled corticosteroids (ICS) by asthmatic children increases their risk for oropharyngeal colonization with Staphylococcus pneumoniae almost fourfo…
Veloxis Pharmaceuticals to Present Data Differentiating LCP-Tacro(TM) from …MarketWatch (press release)HORSHOLM, Denmark, Oct. 10, 2012 /PRNewswire via COMTEX/ — Veloxis will give two upcoming data presentations that further define the profile of LC…
NICE publishes Crohn's management guidanceNursing TimesIt advises that patients who are suffering from the symptoms of Crohn's disease for either the first time or for the first time in a year should be given a glucocorticosteroid such as predn…
Mylan, Shionogi and CIMA Labs to resolve generic Orapred ODT patent litigationNews-Medical.netMylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litiga…
Mylan Announces Settlement Deal For Generic Version Of Orapred ODT – Quick …NASDAQ(RTTNews.com) – Mylan Inc. (MYL) announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation rel…